{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T19:19:26Z","timestamp":1790882366765,"version":"4.1.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T00:00:00Z","timestamp":1786406400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T00:00:00Z","timestamp":1786579200000},"content-version":"vor","delay-in-days":2,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100014584","name":"Universit\u00e4tsmedizin der Johannes Gutenberg-Universit\u00e4t Mainz","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100014584","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Imaging"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Portal hypertension-related parameters are known to have important prognostic implications in patients with hepatocellular carcinoma (HCC). Ascites has consistently been associated with impaired outcomes. However, the prognostic relevance of quantified ascites volume in patients undergoing Atezolizumab\/Bevacizumab remains unclear.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>90 patients with HCC treated with Atezolizumab\/Bevacizumab between 2020 and 2024 were retrospectively included. Ascites was assessed on baseline contrast-enhanced CT imaging using AI-based pre-segmentation followed by manual correction to quantify ascites volume. Overall survival (OS) was analyzed using Kaplan\u2013Meier analysis and Cox regression. Ascites volume was analyzed both as a continuous variable and using predefined volumetric cutoffs (&lt;\u2009613.5 mL and \u2265\u2009613.5 mL).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Ascites was present in 39% of patients, with a median ascites volume of 344 mL (IQR 29\u2013929). When analyzed as a continuous variable, ascites volume was significantly associated with impaired OS in univariate analysis (Hazard Ratio (HR) 2.88,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001) but not after multivariate adjustment (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.214). Stratification by ascites volume revealed a stepwise reduction in OS, with patients without ascites showing the best survival, followed by patients with low-volume ascites (&lt;\u2009613.5\u00a0ml), and patients with high-volume ascites (\u2265\u2009613.5\u00a0ml) demonstrating the poorest outcomes (log-rank\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001). In multivariate analysis, high-volume ascites remained independently associated with impaired OS (HR 4.01,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001), whereas low-volume ascites did not.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Ascites volume showed a threshold-dependent prognostic effect in patients with HCC treated with Atezolizumab\/Bevacizumab. Volumetric staging identifies high-volume ascites as an independent marker of poor outcome and may provide more clinically relevant risk stratification than binary ascites assessment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical trial number<\/jats:title>\n                    <jats:p>Not applicable.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s40644-026-01105-w","type":"journal-article","created":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T15:36:01Z","timestamp":1786462561000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["AI-assisted ascites volumetry for prognostic stratification in HCC treated with Atezolizumab\/Bevacizumab"],"prefix":"10.1186","volume":"26","author":[{"given":"Maximilian","family":"Moos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Bender","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Friedrich","family":"Foerster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucas","family":"Wiesmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arndt","family":"Weinmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roman","family":"Kloeckner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Constantin","family":"Scholz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9","family":"Euler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aline","family":"M\u00e4hringer-Kunz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"B\u00e4uerle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabian","family":"Stoehr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix","family":"Hahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lukas","family":"M\u00fcller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,11]]},"reference":[{"key":"1105_CR1","unstructured":"Asafo-Agyei KO, Samant H. Hepatocellular Carcinoma. StatPearls. Treasure Island (FL): StatPearls Publishing Copyright \u00a9 2025. StatPearls Publishing LLC.; 2025."},{"issue":"3","key":"1105_CR2","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229\u201363.","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"1105_CR3","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.jhep.2018.03.019","volume":"69","author":"PR Galle","year":"2018","unstructured":"Galle PR, Forner A, Llovet JM, Mazzaferro V, Piscaglia F, Raoul J-L, et al. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol. 2018;69(1):182\u2013236.","journal-title":"J Hepatol"},{"issue":"1","key":"1105_CR4","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1002\/hep.29086","volume":"67","author":"JK Heimbach","year":"2018","unstructured":"Heimbach JK, Kulik LM, Finn RS, Sirlin CB, Abecassis MM, Roberts LR, et al. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology. 2018;67(1):358\u201380.","journal-title":"Hepatology"},{"issue":"2","key":"1105_CR5","doi-asserted-by":"publisher","first-page":"124","DOI":"10.17998\/jlc.2021.09.23","volume":"21","author":"BH Kim","year":"2021","unstructured":"Kim BH, Park JW. Systemic therapy for advanced hepatocellular carcinoma: consideration for selecting second-line treatment. J Liver Cancer. 2021;21(2):124\u201338.","journal-title":"J Liver Cancer"},{"issue":"4","key":"1105_CR6","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1016\/j.jhep.2021.11.030","volume":"76","author":"AL Cheng","year":"2022","unstructured":"Cheng AL, Qin S, Ikeda M, Galle PR, Ducreux M, Kim TY, et al. Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma. J Hepatol. 2022;76(4):862\u201373.","journal-title":"J Hepatol"},{"issue":"3","key":"1105_CR7","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1159\/000528272","volume":"12","author":"M Kudo","year":"2023","unstructured":"Kudo M, Finn RS, Galle PR, Zhu AX, Ducreux M, Cheng AL, et al. IMbrave150: Efficacy and Safety of Atezolizumab plus Bevacizumab versus Sorafenib in Patients with Barcelona Clinic Liver Cancer Stage B Unresectable Hepatocellular Carcinoma: An Exploratory Analysis of the Phase III Study. Liver Cancer. 2023;12(3):238\u201350.","journal-title":"Liver Cancer"},{"issue":"12","key":"1105_CR8","doi-asserted-by":"publisher","first-page":"e70379","DOI":"10.1111\/liv.70379","volume":"45","author":"K Ueshima","year":"2025","unstructured":"Ueshima K, Tsuchiya K, Yamashita T, Shimose S, Numata K, Kodama Y, et al. Atezolizumab Plus Bevacizumab for TACE-Unsuitable Intermediate-Stage HCC Beyond Up-To-7 Criteria: Final Analysis of REPLACEMENT. Liver Int. 2025;45(12):e70379.","journal-title":"Liver Int"},{"issue":"3","key":"1105_CR9","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1111\/hepr.13734","volume":"52","author":"A Hiraoka","year":"2022","unstructured":"Hiraoka A, Kumada T, Tada T, Hirooka M, Kariyama K, Tani J, et al. Early experience of atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma BCLC-B stage patients classified as beyond up to seven criteria - Multicenter analysis. Hepatol Res. 2022;52(3):308\u201316.","journal-title":"Hepatol Res"},{"issue":"2","key":"1105_CR10","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/j.cld.2013.12.001","volume":"18","author":"Y Iwakiri","year":"2014","unstructured":"Iwakiri Y. Pathophysiology of portal hypertension. Clin Liver Dis. 2014;18(2):281\u201391.","journal-title":"Clin Liver Dis"},{"issue":"1","key":"1105_CR11","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1136\/gutjnl-2020-321790","volume":"70","author":"GP Aithal","year":"2021","unstructured":"Aithal GP, Palaniyappan N, China L, H\u00e4rm\u00e4l\u00e4 S, Macken L, Ryan JM, et al. Guidelines on the management of ascites in cirrhosis. Gut. 2021;70(1):9\u201329.","journal-title":"Gut"},{"issue":"1","key":"1105_CR12","doi-asserted-by":"publisher","first-page":"16550","DOI":"10.1038\/s41598-024-67312-2","volume":"14","author":"L M\u00fcller","year":"2024","unstructured":"M\u00fcller L, Bender D, Gairing SJ, Foerster F, Weinmann A, Mittler J, et al. Amount of ascites impacts survival in patients with hepatocellular carcinoma undergoing transarterial chemoembolization advocating for volumetric assessment. Sci Rep. 2024;14(1):16550.","journal-title":"Sci Rep"},{"key":"1105_CR13","doi-asserted-by":"crossref","unstructured":"Liao JI, Ho SY, Liu PH, Hsu CY, Huang YH, Su CW et al. Prognostic prediction for patients with hepatocellular carcinoma and ascites: role of albumin-bilirubin (ALBI) grade and easy (EZ)-ALBI grade. Cancers (Basel). 2023;15(3).","DOI":"10.3390\/cancers15030753"},{"issue":"1","key":"1105_CR14","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s40644-023-00558-7","volume":"23","author":"L M\u00fcller","year":"2023","unstructured":"M\u00fcller L, Gairing SJ, Foerster F, Weinmann A, Mittler J, Stoehr F, et al. Portal hypertension in patients with hepatocellular carcinoma and immunotherapy: prognostic relevance of CT-morphologic estimates. Cancer Imaging. 2023;23(1):40.","journal-title":"Cancer Imaging"},{"issue":"1","key":"1105_CR15","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1002\/ueg2.12188","volume":"10","author":"L M\u00fcller","year":"2022","unstructured":"M\u00fcller L, Hahn F, M\u00e4hringer-Kunz A, Stoehr F, Gairing SJ, Foerster F, et al. Prevalence and clinical significance of clinically evident portal hypertension in patients with hepatocellular carcinoma undergoing transarterial chemoembolization. United Eur Gastroenterol J. 2022;10(1):41\u201353.","journal-title":"United Eur Gastroenterol J"},{"key":"1105_CR16","doi-asserted-by":"crossref","unstructured":"Huang PH, Yu J, Chu YY, Lin YH, Yeh CT. Child-pugh score and ABCG2-rs2231142 genotype independently predict survival in advanced hepatoma patients treated with sorafenib. J Clin Med. 2022;11(9).","DOI":"10.3390\/jcm11092550"},{"issue":"4","key":"1105_CR17","doi-asserted-by":"publisher","first-page":"153","DOI":"10.14701\/ahbps.2016.20.4.153","volume":"20","author":"SW Choi","year":"2016","unstructured":"Choi SW, Shin WY, Lee KY, Ahn SI. Risk factors of postoperative ascites on hepatic resection for hepatocellular carcinoma. Ann Hepatobiliary Pancreat Surg. 2016;20(4):153\u20138.","journal-title":"Ann Hepatobiliary Pancreat Surg"},{"key":"1105_CR18","unstructured":"Cardoso MJ, Li W, Brown R, Ma N, Kerfoot E, Wang Y et al. Monai: An open-source framework for deep learning in healthcare. arXiv preprint arXiv:221102701. 2022."},{"issue":"1","key":"1105_CR19","first-page":"1","volume":"48","author":"IROS 2025 Book of Abstracts","year":"2025","unstructured":"IROS 2025 Book of Abstracts. Cardiovasc Interv Radiol. 2025;48(1):1\u201337.","journal-title":"Cardiovasc Interv Radiol"},{"issue":"9","key":"1105_CR20","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1016\/j.mri.2012.05.001","volume":"30","author":"A Fedorov","year":"2012","unstructured":"Fedorov A, Beichel R, Kalpathy-Cramer J, Finet J, Fillion-Robin JC, Pujol S, et al. 3D Slicer as an image computing platform for the Quantitative Imaging Network. Magn Reson Imaging. 2012;30(9):1323\u201341.","journal-title":"Magn Reson Imaging"},{"issue":"11","key":"1105_CR21","doi-asserted-by":"publisher","first-page":"1756","DOI":"10.1111\/jgh.12310","volume":"28","author":"HY Kim","year":"2013","unstructured":"Kim HY, Park JW, Joo J, Kim H, Woo SM, Lee WJ, et al. Worse outcome of sorafenib therapy associated with ascites and Child-Pugh score in advanced hepatocellular carcinoma. J Gastroenterol Hepatol. 2013;28(11):1756\u201361.","journal-title":"J Gastroenterol Hepatol"},{"issue":"9","key":"1105_CR22","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1016\/j.dld.2024.02.018","volume":"56","author":"P Sultanik","year":"2024","unstructured":"Sultanik P, Campani C, Larrey E, Campion B, Evain M, Roux C, et al. Portal hypertension is associated with poorer outcome and clinical liver decompensation in patients with HCC treated with Atezolizumab-Bevacizumab. Dig Liver Dis. 2024;56(9):1621\u201330.","journal-title":"Dig Liver Dis"},{"issue":"8","key":"1105_CR23","doi-asserted-by":"publisher","first-page":"102199","DOI":"10.1016\/j.clinre.2023.102199","volume":"47","author":"S Chaibi","year":"2023","unstructured":"Chaibi S, Larrey E, Couty JP, Sultanik P, Campani C, Blaise L, et al. Albumin infusion reduces ascite occurrence in Child-Pugh B patients treated by Atezolizumab-Bevacizumab for advanced HCC. Clin Res Hepatol Gastroenterol. 2023;47(8):102199.","journal-title":"Clin Res Hepatol Gastroenterol"},{"issue":"6","key":"1105_CR24","first-page":"5733","volume":"14","author":"R Wang","year":"2017","unstructured":"Wang R, Qi X, Guo X. Quantification of ascites based on abdomino-pelvic computed tomography scans for predicting the in-hospital mortality of liver cirrhosis. Exp Ther Med. 2017;14(6):5733\u201342.","journal-title":"Exp Ther Med"},{"key":"1105_CR25","doi-asserted-by":"crossref","unstructured":"Chong Lugon N, Rabiee A, Mezzacappa C, Kaplan DE, Taddei TH, Garcia-Tsao G. Prognostic significance of mild ascites in patients with cirrhosis. Hepatology. 2025.","DOI":"10.1097\/HEP.0000000000001452"},{"issue":"4","key":"1105_CR26","doi-asserted-by":"publisher","first-page":"220","DOI":"10.2478\/jtim-2020-0035","volume":"8","author":"A Gallo","year":"2020","unstructured":"Gallo A, Dedionigi C, Civitelli C, Panzeri A, Corradi C, Squizzato A. Optimal Management of Cirrhotic Ascites: A Review for Internal Medicine Physicians. J Transl Int Med. 2020;8(4):220\u201336.","journal-title":"J Transl Int Med"},{"issue":"8","key":"1105_CR27","doi-asserted-by":"publisher","first-page":"100513","DOI":"10.1016\/j.jhepr.2022.100513","volume":"4","author":"L Balcar","year":"2022","unstructured":"Balcar L, Tonon M, Semmler G, Calvino V, Hartl L, Incicco S, et al. Risk of further decompensation\/mortality in patients with cirrhosis and ascites as the first single decompensation event. JHEP Rep. 2022;4(8):100513.","journal-title":"JHEP Rep"},{"issue":"1","key":"1105_CR28","first-page":"93","volume":"34","author":"T Theodorakopoulos","year":"2021","unstructured":"Theodorakopoulos T, Kalafateli M, Kalambokis GN, Samonakis DN, Aggeletopoulou I, Tsolias C, et al. Natural history of grade 1 ascites in patients with liver cirrhosis. Ann Gastroenterol. 2021;34(1):93\u2013103.","journal-title":"Ann Gastroenterol"},{"issue":"3","key":"1105_CR29","doi-asserted-by":"publisher","first-page":"230","DOI":"10.3350\/cmh.2018.1005","volume":"24","author":"KASL clinical practice guidelines for liver cirrhosis","year":"2018","unstructured":"KASL clinical practice guidelines for liver cirrhosis. Ascites and related complications. Clin Mol Hepatol. 2018;24(3):230\u201377.","journal-title":"Clin Mol Hepatol"},{"issue":"4","key":"1105_CR30","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1016\/j.jhep.2021.07.004","volume":"75","author":"J Bruix","year":"2021","unstructured":"Bruix J, Chan SL, Galle PR, Rimassa L, Sangro B. Systemic treatment of hepatocellular carcinoma: An EASL position paper. J Hepatol. 2021;75(4):960\u201374.","journal-title":"J Hepatol"},{"issue":"5","key":"1105_CR31","doi-asserted-by":"publisher","first-page":"e230601","DOI":"10.1148\/ryai.230601","volume":"6","author":"B Hou","year":"2024","unstructured":"Hou B, Lee S, Lee JM, Koh C, Xiao J, Pickhardt PJ, et al. Deep Learning Segmentation of Ascites on Abdominal CT Scans for Automatic Volume Quantification. Radiol Artif Intell. 2024;6(5):e230601.","journal-title":"Radiol Artif Intell"},{"issue":"7","key":"1105_CR32","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1093\/jjco\/hyi109","volume":"35","author":"N Oriuchi","year":"2005","unstructured":"Oriuchi N, Nakajima T, Mochiki E, Takeyoshi I, Kanuma T, Endo K, et al. A new, accurate and conventional five-point method for quantitative evaluation of ascites using plain computed tomography in cancer patients. Jpn J Clin Oncol. 2005;35(7):386\u201390.","journal-title":"Jpn J Clin Oncol"}],"container-title":["Cancer Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40644-026-01105-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40644-026-01105-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40644-026-01105-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T07:47:16Z","timestamp":1786607236000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s40644-026-01105-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,11]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1105"],"URL":"https:\/\/doi.org\/10.1186\/s40644-026-01105-w","relation":{},"ISSN":["1470-7330"],"issn-type":[{"value":"1470-7330","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,11]]},"assertion":[{"value":"23 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This retrospective study was approved by the local ethics committee of Rhineland-Palatinate. Informed consent was waived by the ethics committee (permit number 2021\u201315,984).","order":1,"name":"Ethics","label":"Ethical approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"FF has received Honoria as a speaker and\/or consultant from AstraZeneca, Bluejay Therapeutics, BMS, Eisai, Lilly, MSD, Pfizer, Roche, Taiho and Takeda and reimbursement of meeting attendance fees and travel expenses from BeOne Medicines, Merck, KGaA and Servier. AE is part of the speaker\u2019s bureau auf Siemens Healthcare GmbH.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"105"}}